Lumasiran sodiumProduct ingredient for Lumasiran

Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).⁶ This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.⁶ These patients experience frequent kidney stones, nephrocalcinosis, and renal failure.⁶

Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1.³ Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, pyridoxine, and renal transplant.⁶

Lumasiran was granted FDA approval on 23 November 2020.³

Wikipedia

Lumasiran